SCHEMBL966543

SCHEMBL966543

C[C@@H](C(N)=O)c1ccccc1NS(C)(=O)=O

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.65
CXCL8 P10145 2/20 0.55
HSD17B10 Q99714 3/20 0.47
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 2/20 0.47
HPGD P15428 2/20 0.47
KMT2A Q03164 1/20 0.46
POLB P06746 1/20 0.44
KEAP1 Q14145 2/20 0.44
EP300 Q09472 1/20 0.41
KAT2B Q92831 1/20 0.41
KAT8 Q9H7Z6 1/20 0.41
TSHR P16473 1/20 0.41
PLA2G7 Q13093 1/20 0.41
NFE2L2 Q16236 1/20 0.41
GAA P10253 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5673731 1.00 L3MBTL1 (0.65) L3MBTL1CXCL8HSD17B10KDM4EALDH1A1
SCHEMBL8507281 0.84 L3MBTL1 (0.65) L3MBTL1CXCL8HSD17B10KDM4EALDH1A1
SCHEMBL2635013 0.83 L3MBTL1 (0.63) L3MBTL1CXCL8HSD17B10KDM4EALDH1A1
SCHEMBL5995240 0.80 L3MBTL1 (0.55) L3MBTL1HSD17B10KDM4EALDH1A1HPGD
SCHEMBL5607024 0.79 L3MBTL1 (1.00) L3MBTL1HSD17B10KDM4EALDH1A1HPGD
SCHEMBL28139178 0.79 L3MBTL1 (0.58) L3MBTL1CXCL8HSD17B10KDM4EALDH1A1
SCHEMBL1888587 0.77 CXCL8 (0.57) CXCL8HSD17B10ALDH1A1HPGDPOLB
SCHEMBL9321170 0.76 CXCL8 (0.54) L3MBTL1CXCL8HSD17B10HPGDKMT2A
SCHEMBL16539266 0.75 CXCL8 (0.64) CXCL8KDM4EALDH1A1HPGDKMT2A
SCHEMBL16896758 0.75 MMP2 (0.45) L3MBTL1CXCL8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2024329-B1 (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE SPA (IT) 2013-07-31 EP disclosed
US-7868046-B2 (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them DOMPE' PHA.R.MA S.P.A. (IT) 2011-01-11 US disclosed
US-20100152256-A1 (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them DOMPE' PHA.R.MA S.P.A. (IT) 2010-06-17 US disclosed
US-7652169-B2 (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them Dompe' Pha. R. Ma S.p.A. (IT) 2010-01-26 US disclosed
US-20090093530-A1 (2R)-2-[4-Sulfonyl) Aminophenyl] Propanamides and Pharmaceutical Compositions Containing Them DOMPÉ FARMACEUTICI S.P.A. (IT) 2009-04-09 US disclosed
EP-2024329-A2 (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE' pha.r.ma s.p.a. (IT) 2009-02-18 EP disclosed
WO-2007135080-A2 (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE' PHA.R.MA. S.P.A. (IT) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152256-A1 (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them CCR2, CXCR2, CXCR4 L3MBTL1 3027/4885CXCL8 181/4885HSD17B10 4633/4885
US-20090093530-A1 (2R)-2-[4-Sulfonyl) Aminophenyl] Propanamides and Pharmaceutical Compositions Containing Them CCR2, CXCR2, CXCR3 L3MBTL1 3868/4885CXCL8 92/4885HSD17B10 4731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.